Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: New recurrence-free survival results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial at three-year median follow-up.

被引：0

作者：

Eggermont, Alexander M.

Blank, Christian U.

Mandala, Mario

Long, Georgina V.

Atkinson, Victoria

Dalle, Stephane

Haydon, Andrew Mark

Meshcheryakov, Andrey

Khattak, Muhammad

Carlino, Matteo S.

Sandhu, Shahneen Kaur

Puig, Susana

Ascierto, Paolo Antonio

Christopher, Alexander

Van Akkooi, Jonathan

Krepler, Clemens

Ibrahim, Nageatte

Marreaud, Sandrine

Kicinski, Michal

Suciu, Stefan

Robert, Caroline

机构：

[1] Princess Maxima Ctr, Utrecht, Netherlands

[2] Netherlands Canc Inst, Amsterdam, Netherlands

[3] ASST Papa Giovanni XXIII, Bergamo, Italy

[4] Univ Sydney, Melanoma Inst Australia, Royal North Shore Hosp, Mater Hosp, Sydney, NSW, Australia

[5] Univ Queensland, Brisbane, Qld, Australia

[6] Hosp Civils Lyon, Pierre Benite, France

[7] Alfred Hosp, Melbourne, Vic, Australia

[8] NN Blokhin Canc Res Ctr, Moscow, Russia

[9] Univ Western Australia, Fiona Stanley Hosp, Perth, WA, Australia

[10] Westmead Hosp, Sydney, NSW, Australia

[11] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia

[12] Hosp Clin Barcelona, Barcelona, Spain

[13] Fdn IRCCS Ist Nazl Tumori, Naples, Italy

[14] Antoni van Leeuwenhoek Hosp, Netherlands Canc Inst, Amsterdam, Netherlands

[15] Wistar Inst Anat & Biol, Philadelphia, PA USA

[16] Merck & Co Inc, Kenilworth, NJ USA

[17] EORTC Headquarters, Brussels, Belgium

[18] Gustave Roussy, Villejuif, France

[19] Paris Saclay Univ, Villejuif, France

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2020年 / 38卷 / 15期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

10000

引用

页数：2

共 26 条

[1] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Efficacy and safety results from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Eggermont, Alexander M.
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria
Dalle, Stephane
Haydon, Andrew
Lichinitser, Mikhail
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Maio, Michele
van den Eertwegh, Alfonsus J.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Rivas, Veronica
Ibrahim, Nageatte
Marreaud, Sandrine
Janssen, Sven
van Akkooi, Alexander
Suciu, Stefan
Robert, Caroline
CANCER RESEARCH, 2018, 78 (13)
[2] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: 5-year results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. S. Puig
Ascierto, P. A.
Lorigan, P.
Grebennik, D.
Ibrahim, N.
Marreaud, S. I.
Suciu, S.
Robert, C.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S912 - S913
[3] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Final results regarding distant metastasis-free survival from the EORTC 1325-MG/Keynote 054 double-blinded phase III trial
Eggermont, A. M. M.
Blank, C. U.
Mandala', M.
Long, G. V.
Atkinson, V.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, A.
Carlino, M.
Sandhu, S.
Sarda, S. Puig
Ascierto, P. A.
van Akkooi, A. C. J.
Krepler, C.
Ibrahim, N.
Marreaud, S. I.
Kicinski, M.
Suciu, S.
Robert, C.
ANNALS OF ONCOLOGY, 2020, 31 : S1175 - S1175
[4] Pembrolizumab versus placebo after complete resection of high-risk stage III melanoma: Long-term quality of life analysis results of the EORTC 1325-MG/Keynote-054 double-blinded phase III trial
Bottomley, A.
Kicinski, M.
Long, G. V.
Mandala, M.
Atkinson, V. G.
Blank, C. U.
Haydon, A. M.
Dalle, S.
Khattak, A.
Carlino, M. S.
Meshcheryakov, A.
Sandhu, S. K.
Puig Sarda, S. S.
Coens, C.
Suciu, S.
Grebennik, D.
Krepler, C.
Lorigan, P.
Robert, C.
Eggermont, A. M. M.
ANNALS OF ONCOLOGY, 2022, 33 (07) : S1410 - S1411
[5] Pembrolizumab versus placebo after a complete resection of high-risk stage III melanoma: 7-year results of the EORTC 1325-MG/Keynote-054 double-blind phase III trial
Eggermont, A. M. M.
Kicinski, M.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V. G.
Dalle, S.
Haydon, A. M.
Meshcheryakov, A.
Khattak, M. A.
Carlino, M. S.
Sandhu, S. K.
Sarda, S. Puig
Ascierto, P. A.
Lorigan, P.
Grebennik, D.
Krepler, C.
Marreaud, S. I.
Suciu, S.
Robert, C.
ANNALS OF ONCOLOGY, 2024, 35 : S725 - S726
[6] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase III trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma
Eggermont, Alexander M. M.
Meshcheryakov, Andrey
Atkinson, Victoria
Blank, Christian U.
Mandala, Mario
Long, Georgina, V
Barrow, Catherine
Di Giacomo, Anna Maria
Fisher, Rosalie
Sandhu, Shahneen
Kudchadkar, Ragini
Romero, Pablo Luis Ortiz
Svane, Inge Marie
Larkin, James
Puig, Susana
Hersey, Peter
Quaglino, Pietro
Queirolo, Paola
Stroyakovskiy, Daniil
Bastholt, Lars
Mohr, Peter
Hernberg, Micaela
Chiarion-Sileni, Vanna
Strother, Matthew
Hauschild, Axel
Yamazaki, Naoya
van Akkooi, Alexander Cj
Lorigan, Paul
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
EUROPEAN JOURNAL OF CANCER, 2021, 158 : 156 - 168
[7] Phase 3 Randomized Eortc 1325-Mg/Keynote-054 Study Results: Pembrolizumab Versus Placebo after Complete Resection in Patients with High-Risk Stage III Melanoma
Khattak, A.
Robert, C.
Blank, C. U.
Mandala, M.
Long, G. V.
Atkinson, V.
Dalle, S.
Haydon, A.
Lichinitser, M.
Carlino, M. S.
Sandhu, S.
Larkin, J.
Puig, S.
Ascierto, P. A.
Rutkowski, P.
Schadendorf, D.
Lorigan, P.
Ibrahim, N.
Suciu, S.
Eggermont, A. M. M.
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2018, 14 : 48 - 48
[8] Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
Eggermont, Alexander M. M.
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Atkinson, Victoria G.
Dalle, Stephane
Haydon, Andrew M.
Meshcheryakov, Andrey
Khattak, Adnan
Carlino, Matteo S.
Sandhu, Shahneen
Larkin, James
Puig, Susana
Ascierto, Paolo A.
Rutkowski, Piotr
Schadendorf, Dirk
Koornstra, Rutger
Hernandez-Aya, Leonel
Di Giacomo, Anna Maria
van den Eertwegh, Alfonsus J. M.
Grob, Jean-Jacques
Gutzmer, Ralf
Jamal, Rahima
Lorigan, Paul C.
van Akkooi, Alexander C. J.
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (33)
[9] Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.
Eggermont, Alexander M.
Meshcheryakov, Andrey
Atkinson, Victoria
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Barrow, Catherine
Di Giacomo, Anna Maria
Stephens, Rosalie
Sandhu, Shahneen Kaur
Kudchadkar, Ragini Reiney
Ortiz-Romero, Pablo L.
Svane, Inge Marie
Van Akkooi, Alexander Christopher Jonathan
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
[10] EORTC 1325-MG/KEYNOTE-054 phase 3 trial of pembrolizumab versus placebo for completely resected high-risk stage III melanoma: pembrolizumab crossover and rechallenge following recurrence
Atkinson, Victoria
Eggermont, Alexander M. M.
Meshcheryakov, Andrey
Blank, Christian U.
Mandala, Mario
Long, Georgina V.
Barrow, Catherine
Di Giacomo, Anna Maria
Fisher, Rosalie
Sandhu, Shahneen
Kudchadkar, Ragini
Ortiz Romero, Pablo Luis
Svane, Inge Marie
van Akkooi, Alexander
Krepler, Clemens
Ibrahim, Nageatte
Marreaud, Sandrine
Kicinski, Michal
Suciu, Stefan
Robert, Caroline
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2021, 17 : 161 - 161

← 1 2 3 →